Thiocolchicoside is a semi-synthetic muscle relaxant derived from the natural alkaloid colchicoside, with potent central and peripheral muscle relaxant, analgesic, and anti-inflammatory properties. It acts as a competitive GABA-A receptor antagonist at the spinal cord and supraspinal levels, leading to muscle relaxation. It is widely used in the Indian clinical setting for painful musculoskeletal conditions.
Adult: 8 mg twice daily. The total daily dose should not exceed 16 mg. Treatment duration should be as short as possible, typically not exceeding 7-10 days for acute conditions.
Note: To be taken after food to minimize gastric irritation. Tablet should be swallowed whole with a glass of water. Do not crush or chew. The last dose should preferably not be taken immediately before bedtime due to potential drowsiness.
Thiocolchicoside competitively and selectively blocks the GABA-A receptor at the postsynaptic level in the spinal cord and brain. This blockade inhibits the GABA-mediated inhibitory neurotransmission, leading to a reduction in the frequency and amplitude of motor neuron action potentials, resulting in muscle relaxation. It also exhibits a glycine-mimetic action at the spinal level and possesses anti-inflammatory and analgesic effects, likely through inhibition of prostaglandin synthesis and cytokine release.
Pregnancy: Category C (US FDA). Animal studies have shown teratogenicity. There are no adequate and well-controlled studies in pregnant women. Should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, especially in the first trimester. Avoid in late pregnancy.
Driving: May impair alertness and motor coordination. Patients should be cautioned against driving or operating heavy machinery, especially during initial therapy or dose escalation.
| CNS Depressants (Alcohol, Benzodiazepines, Opioids) | Potentiation of sedative effects, increased risk of drowsiness, dizziness, and impaired coordination. | Major |
| Other Muscle Relaxants (Baclofen, Tizanidine) | Additive muscle relaxation, increasing risk of weakness and sedation. | Major |
| NSAIDs (Diclofenac, Aceclofenac in FDCs) | Increased risk of gastrointestinal bleeding, ulceration, and nephrotoxicity. | Major |
| Antihypertensives | May potentiate hypotensive effects. | Moderate |
| Enzyme Inducers (Phenobarbital, Rifampicin) | May decrease plasma levels of Thiocolchicoside by increasing its metabolism. | Moderate |
| Enzyme Inhibitors (Cimetidine, Fluconazole) | May increase plasma levels of Thiocolchicoside, increasing risk of toxicity. | Moderate |
Same composition (Thiocolchicoside (8mg)), different brands: